Repligen (RGEN) Reports In-Line Q3 EPS
Get Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $15.3 million versus the consensus estimate of $15.6 million.
Repligen sees FY2014 revenue of $60-62 million, versus prior guidance of $59-62 million and the consensus of $0.28 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share